Supply of 4D-Nucleofector X Unit (CLIN 2)

The contract seeks the procurement and delivery of a single 4D-Nucleofector X Unit or an equivalent device capable of high-throughput nucleofection with preprogrammed protocols specifically validated for primary human dendritic cells. This equipment is intended to support advanced cellular research and therapeutic development under the auspices of the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services. The device must meet exact technical specifications to ensure compatibility with existing protocols and to enable consistent, reproducible transfection results critical for clinical and research applications. This is designated as a subcontract under NAICS code 334516, with a posted date of July 26, 2026, and a response deadline of August 3, 2026. The place of performance and point of contact details are not specified, and no set-aside provisions are identified. Interested parties must submit proposals prior to the stated deadline to be considered for award, and the solution must demonstrate proven efficacy in handling sensitive primary human cell types without compromising viability or transfection efficiency. The procurement is part of broader efforts to enhance laboratory capabilities for immunological and cellular therapy research.